Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Aclaris Therapeutics Inc (NASDAQ: ACRS) closed at $1.46 in the last session, up 1.39% from day before closing price of $1.44. In other words, the price has increased by $1.39 from its previous closing price. On the day, 0.57 million shares were traded. ACRS stock price reached its highest trading level at $1.5 during the session, while it also had its lowest trading level at $1.435.
Ratios:
We take a closer look at ACRS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.06 and its Current Ratio is at 5.06. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wedbush on May 28, 2025, initiated with a Outperform rating and assigned the stock a target price of $8.
H.C. Wainwright Upgraded its Neutral to Buy on December 23, 2024, while the target price for the stock was maintained at $20.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 19 ’24 when Mehra Anand bought 666,666 shares for $2.25 per share. The transaction valued at 1,499,998 led to the insider holds 710,030 shares of the business.
Leonard Braden Michael bought 206,025 shares of ACRS for $256,357 on Aug 05 ’24. The 10% Owner now owns 14,250,000 shares after completing the transaction at $1.24 per share. On Aug 02 ’24, another insider, Leonard Braden Michael, who serves as the 10% Owner of the company, bought 167,544 shares for $1.29 each. As a result, the insider paid 216,400 and bolstered with 14,043,975 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACRS now has a Market Capitalization of 158090272 and an Enterprise Value of 50929360. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.89 while its Price-to-Book (P/B) ratio in mrq is 1.10. Its current Enterprise Value per Revenue stands at 2.865 whereas that against EBITDA is -0.943.
Stock Price History:
The Beta on a monthly basis for ACRS is 0.31, which has changed by 0.15873015 over the last 52 weeks, in comparison to a change of 0.11708844 over the same period for the S&P500. Over the past 52 weeks, ACRS has reached a high of $5.17, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 4.64%, while the 200-Day Moving Average is calculated to be -24.84%.
Shares Statistics:
According to the various share statistics, ACRS traded on average about 960.38K shares per day over the past 3-months and 1909050 shares per day over the past 10 days. A total of 108.27M shares are outstanding, with a floating share count of 92.25M. Insiders hold about 14.81% of the company’s shares, while institutions hold 75.05% stake in the company. Shares short for ACRS as of 1749772800 were 4843301 with a Short Ratio of 5.04, compared to 1747267200 on 4568208. Therefore, it implies a Short% of Shares Outstanding of 4843301 and a Short% of Float of 5.33.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The performance of Aclaris Therapeutics Inc (ACRS) in the stock market is under the watchful eye of 5.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.13 and low estimates of -$0.18.
Analysts are recommending an EPS of between -$0.53 and -$0.62 for the fiscal current year, implying an average EPS of -$0.58. EPS for the following year is -$0.69, with 5.0 analysts recommending between -$0.58 and -$0.87.
Revenue Estimates
According to 6 analysts, the current quarter’s revenue is expected to be $1.33M. It ranges from a high estimate of $2.7M to a low estimate of $300k. As of the current estimate, Aclaris Therapeutics Inc’s year-ago sales were $2.77MFor the next quarter, 6 analysts are estimating revenue of $1.42M. There is a high estimate of $2.7M for the next quarter, whereas the lowest estimate is $600k.
A total of 5 analysts have provided revenue estimates for ACRS’s current fiscal year. The highest revenue estimate was $9.6M, while the lowest revenue estimate was $3.1M, resulting in an average revenue estimate of $6.14M. In the same quarter a year ago, actual revenue was $18.72MBased on 7 analysts’ estimates, the company’s revenue will be $10.77M in the next fiscal year. The high estimate is $44.7M and the low estimate is $900k.
